Monday, January 26, 2015 3:48:42 PM
Believing that better cells lead to better medicine, VistaGen Therapeutics has been applying pluripotent stem cell technology toward drug rescue, predictive toxicology and drug metabolism screening.
VistaGen’s activities are guided by the belief that the key to making better cells is strictly controlling the differentiation of human pluripotent stem cells, the building blocks of all cells in the human body. For more than 15 years, the company’s stem cell research and development teams and collaborators have developed proprietary methods for controlling the differentiation of human pluripotent stem cells and the production and maturation of several specific types of adult human cells, particularly human heart and liver cells.
VistaGen’s drug rescue activities are focused on combining its stem cell technology and assay development expertise with modern medicinal chemistry to produce drug rescue variants – new, safer chemical variants of once-promising drug candidates that have positive data supporting their therapeutic and commercial potential, but that were halted in development by the pharmaceutical companies or university laboratories because of concerns about potential heart or liver toxicity or metabolism issues.
In the years since VistaGen was founded, the California-based biotechnology company has developed two customized bioassay systems designed to transform drug development by establishing clinically-predictive, human cell-based toxicology screening at the front end of the development process, long before animal or human studies:
• CardioSafe 3D™ – This customized human heart cell bioassay system for screening potential heart toxicity of new drug candidates uses mature, functional, adult human heart cells produced from pluripotent stem cells (VSTA-CMs™) to detect a far broader range of potential cardiac toxicities than the FDA-required hERG assay, and it provides proprietary cardiac toxicity and quantitative structure-function (QSAR) information to guide highly-efficient selection and development of proprietary drug rescue candidates for VistaGen’s pipeline.
• LiverSafe 3D™ – VistaGen is developing and validating this innovative, three-dimensional in-vitro bioassay system designed to evaluate liver toxicity and drug metabolism issues. LiverSafe 3D uses VSTA-heps™, VistaGen’s pluripotent stem cell-derived, mature adult human hepatocytes (liver cells). VSTA-heps have significantly more functionally useful life span in culture than primary (cadaver) hepatocytes and overcome the key problems related to use of primary hepatocytes for in vitro liver safety toxicity and drug metabolism screening, including: extreme variation in functional activity; limited supply; unknown health status of donor; and genetic differences.
VistaGen continues employ its world-class stem cell differentiation and bioassay development expertise to expand the scope of its drug rescue, drug discovery and strategic collaboration opportunities worldwide.
For more information, visit the company’s website at www.vistagen.com
Recent VTGN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 09:00:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 09:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 09:00:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 09:00:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2024 08:07:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:53:06 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:49:59 PM
- Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update • Business Wire • 08/13/2024 08:21:00 PM
- Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024 • Business Wire • 08/06/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2024 08:27:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2024 08:34:14 PM
- Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine • Business Wire • 07/09/2024 12:30:00 PM
- Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year • Business Wire • 06/27/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:27:53 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/11/2024 08:27:09 PM
- Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update • Business Wire • 06/11/2024 08:20:00 PM
- U.S. Index Futures Fall Ahead of Federal Reserve Policy Meeting, Crude Oil Prices Decline • IH Market News • 06/11/2024 11:07:13 AM
- Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024 • Business Wire • 06/07/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:10:11 PM
- Vistagen to Present at the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 12:30:00 PM
- Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference • Business Wire • 05/23/2024 12:30:00 PM
- Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference • Business Wire • 05/07/2024 12:30:00 PM
- Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue • Business Wire • 04/25/2024 12:30:00 PM
- Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference • Business Wire • 04/09/2024 12:30:00 PM
- Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 • Business Wire • 04/01/2024 12:30:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM